ZIOPHARM Oncology, Inc. News Releases https://ir.ziopharm.com/ ZIOPHARM Oncology, Inc. News Releases en Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-reports-first-quarter-2019-financial-results - Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin at NCI in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 –   - Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo ® for  patients Wed, 08 May 2019 16:03:00 -0400 ZIOPHARM Oncology, Inc. News Releases 15466 Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019 https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-host-conference-call-discuss-first-quarter BOSTON , May 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended March 31 , 2019.  Wed, 01 May 2019 16:10:00 -0400 ZIOPHARM Oncology, Inc. News Releases 15456 Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-announces-fda-fast-track-designation-ad-rts BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its Controlled Mon, 01 Apr 2019 07:00:00 -0400 ZIOPHARM Oncology, Inc. News Releases 15436 Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-reports-fourth-quarter-and-full-year-2018 - Phase 1 Trial of Sleeping Beauty -TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 –   - Eden BioCell to advance third-generation Sleeping Beauty CAR-T for Tue, 05 Mar 2019 16:01:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15421 Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5 https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-announce-fourth-quarter-and-full-year-2018 BOSTON , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Tuesday, March 5 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and Mon, 25 Feb 2019 07:50:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15411 Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-ceo-present-car-tcr-summit-europe BOSTON , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper , M.D., Ph.D, is scheduled to present and participate in a panel discussion on Feb. 26 at the CAR-TCR Summit Europe in London . Thu, 21 Feb 2019 08:30:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15396 Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-completes-enrollment-controlled-il-12 -- Substudy promptly accrued 36 patients in less than six months, with majority of newly enrolled patients receiving low-dose steroids -- BOSTON , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that it rapidly completed enrollment and treated a total of 36 Mon, 11 Feb 2019 07:45:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15376 Ziopharm Oncology Presenting at the 37th Annual J.P. Morgan Healthcare Conference https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-presenting-37th-annual-jp-morgan-healthcare BOSTON, MA, January 10, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) Laurence Cooper, M.D., Ph.D., Chief Executive Officer, today is presenting at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco at 9 a.m. PT/12 noon ET. Thu, 10 Jan 2019 11:30:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15341 Ziopharm Oncology Posts Letter to Stockholders https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-posts-letter-stockholders BOSTON , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us, we wanted to communicate directly with our shareholders. Mon, 07 Jan 2019 16:01:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15301 Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-responds-recent-stock-decline-and-clarifies BOSTON , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018 , the same day that the broader market and all indexes were up significantly. Thu, 27 Dec 2018 13:16:00 -0500 ZIOPHARM Oncology, Inc. News Releases 15261